Peptide directoryGut, pancreas & liver

GLP-1 (7-37)

GLP-1 with one extra glycine: the same signal in a slightly longer coat.

Where it comes from

Made in
L cells of the ileum and colon
Sent out by
Nutrients reaching the lower gut after a meal, alongside the 7-36 amide
Acts on
  • Pancreatic beta cells
  • Pancreatic alpha cells
  • Stomach
  • Hypothalamus and brainstem

What it does

  • Equal to GLP-1 (7-36 amide) at the receptor 1
  • Cleared as fast, by DPP-4 within minutes
  • Counted with the other forms in “total GLP-1” assays 2

In medicine

  • The approved GLP-1 medicines are built on this sequence as much as on 7-36: liraglutide and semaglutide end at glycine 37 1
  • Exenatide and lixisenatide come from a lizard peptide that shares about half the sequence

Beyond the body’s own use

  • No trial has compared the two forms in people and no medicine distinguishes them, so everything the evidence says of GLP-1 applies to both 1
  • Assays that measure it apart from the 7-36 amide exist for research. Why the gut makes two forms at all, and whether the ratio between them shifts in disease or after bariatric surgery, is still open 2
  • Its working life is as a reference standard, which is how the gap between “total” and “active” GLP-1 numbers in older papers was traced 2

Sources

  1. Gasbjerg et al., Proglucagon-derived peptides: human physiology and therapeutic potential, Physiological Reviews 2026
  2. Holst, The physiology of glucagon-like peptide 1, Physiological Reviews 2007

This card describes what a medicine is for and what the evidence says; it recommends nothing. Talk to your clinician about anything you read here.